{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:24:41Z","timestamp":1780089881023,"version":"3.54.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.iac.2023.04.010","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T06:55:38Z","timestamp":1685861738000},"page":"681-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis"],"prefix":"10.1016","volume":"43","author":[{"given":"Theo","family":"Gulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2023.04.010_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.21.120601.141025","article-title":"Mast cells as \"tunable\" effector and immunoregulatory cells: recent advances","volume":"23","author":"Galli","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib2","first-page":"13","article-title":"The mast cell: a multifunctional effector cell","volume":"7","author":"Crivellato","year":"2003","journal-title":"Adv Clin Path"},{"key":"10.1016\/j.iac.2023.04.010_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/978-1-4419-9533-9_1","article-title":"Mast cell biology: introduction and overview","volume":"716","author":"Gilfillan","year":"2011","journal-title":"Adv Exp Med Biol"},{"issue":"23","key":"10.1016\/j.iac.2023.04.010_bib4","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich\u2019s visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdermsci.2007.09.009","article-title":"Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis","volume":"49","author":"Galli","year":"2008","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.iac.2023.04.010_bib6","first-page":"43","article-title":"Roles of adaptor molecules in mast cell activation","volume":"87","author":"Iwaki","year":"2005","journal-title":"Chem Immunol Allergy"},{"issue":"7","key":"10.1016\/j.iac.2023.04.010_bib7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1615\/CritRevImmunol.v31.i6.30","article-title":"Regulation of mast cell responses in health and disease","volume":"31","author":"Gilfillan","year":"2011","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaip.2019.09.038","article-title":"MRGPRX2 signaling and skin test results","volume":"8","author":"Kelso","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.iac.2023.04.010_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000315937","article-title":"Anaphylaxis: mechanisms of mast cell activation","volume":"95","author":"Kalesnikoff","year":"2010","journal-title":"Chem Immunol Allergy"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.all.0000162306.12728.c2","article-title":"The role of genetics in the development of asthma and atopy","volume":"5","author":"Blumenthal","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaci.2011.08.033","article-title":"Low incidence and high remission of allergic sensitization among adults","volume":"129","author":"Warm","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000351416","article-title":"Prevalence of atopy and respiratory allergic diseases in the elderly SAPALDIA population","volume":"162","author":"W\u00fcthrich","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib15","doi-asserted-by":"crossref","first-page":"e2020012","DOI":"10.5620\/eaht.2020012","article-title":"Age-period-cohort analysis of asthma, allergic rhinitis, and atopic dermatitis prevalence in Japan","volume":"35","author":"Okui","year":"2020","journal-title":"Environ Anal Health Toxicol"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.iac.2021.09.001","article-title":"Anaphylaxis: Definition, Epidemiology, Diagnostic Challenges, Grading System","volume":"42","author":"Bagos-Estevez","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000315935","article-title":"Epidemiology of anaphylaxis","volume":"95","author":"Worm","year":"2010","journal-title":"Chem Immunol Allergy"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2008.09.043","article-title":"The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project","volume":"122","author":"Decker","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2023.04.010_bib20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/all.12272","article-title":"The epidemiology of anaphylaxis in Europe: a systematic review","volume":"68","author":"Panesar","year":"2013","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1258\/jrsm.2008.070306","article-title":"Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England","volume":"101","author":"Sheikh","year":"2008","journal-title":"J\u00a0R Soc Med"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1398-9995.2005.00785.x","article-title":"Epidemiology of life-threatening and lethal anaphylaxis: a review","volume":"60","author":"Moneret-Vautrin","year":"2005","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jaci.2015.11.015","article-title":"Anaphylaxis in children and adolescents: The European Anaphylaxis Registry","volume":"137","author":"Grabenhenrich","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"21","key":"10.1016\/j.iac.2023.04.010_bib24","first-page":"367","article-title":"Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland","volume":"111","author":"Worm","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson","year":"2006","journal-title":"Ann Emerg Med"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/joim.12410","article-title":"Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease","volume":"279","author":"Gulen","year":"2016","journal-title":"J\u00a0Intern Med"},{"issue":"11","key":"10.1016\/j.iac.2023.04.010_bib27","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.iac.2023.04.010_bib28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","article-title":"Prevalence of indolent systemic mastocytosis in a Dutch region","volume":"131","author":"van Doormaal","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iac.2023.04.010_bib30","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.3390\/cancers13246380","article-title":"A\u00a0Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years\u2019 Experience of the GISM Network","volume":"13","author":"Zanotti","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.iac.2023.04.010_bib31","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.3390\/cancers14163942","article-title":"Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience","volume":"14","author":"Ungerstedt","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"9928","key":"10.1016\/j.iac.2023.04.010_bib34","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(14)60585-7","article-title":"Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis","volume":"383","author":"Gulen","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.iac.2023.04.010_bib35","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000096442","article-title":"Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome","volume":"142","author":"Sonneck","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.iac.2023.04.010_bib38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonzalez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2023.04.010_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1398-9995.1990.tb00945.x","article-title":"Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa","volume":"45","author":"Muller","year":"1990","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2023.04.010_bib40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaip.2017.02.008","article-title":"Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis","volume":"5","author":"Gulen","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib41","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2023.04.010_bib42","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/all.13207","article-title":"Patterns of anaphylaxis after diagnostic workup: a follow-up study of 226 patients with suspected anaphylaxis","volume":"72","author":"Oropeza","year":"2017","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jaip.2015.11.027","article-title":"alpha-Gal-a new clue for anaphylaxis in mastocytosis","volume":"4","author":"Roenneberg","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.iac.2023.04.010_bib44","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.jaip.2020.05.044","article-title":"Low frequency of IgE-mediated food hypersensitivity in mastocytosis","volume":"8","author":"Jarkvist","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib45","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0310057X0903700415","article-title":"Anaphylactoid reaction to intravenous contrast in patient with systemic mastocytosis","volume":"37","author":"Weingarten","year":"2009","journal-title":"Anaesth Intensive Care"},{"issue":"5","key":"10.1016\/j.iac.2023.04.010_bib46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12630-011-9472-z","article-title":"Case report: perioperative immediate hypersensitivity involves not only allergy but also mastocytosis","volume":"58","author":"Renauld","year":"2011","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.iac.2023.04.010_bib47","doi-asserted-by":"crossref","first-page":"1071807","DOI":"10.3389\/falgy.2022.1071807","article-title":"Non-steroidal anti-inflammatory drug-induced anaphylaxis infrequent in 388 patients with mastocytosis: A two-center retrospective cohort study","volume":"3","author":"Bonadonna","year":"2022","journal-title":"Front. Allergy"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib48","doi-asserted-by":"crossref","first-page":"e12132","DOI":"10.1002\/clt2.12132","article-title":"Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclooxygenase inhibitors: prevalence, clinical, and laboratory features","volume":"12","author":"Rama","year":"2022","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1710-1492-10-19","article-title":"Non-steroidal anti-inflammatory drug hypersensitivity: association with elevated basal serum tryptase?","volume":"10","author":"Seitz","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2023.04.010_bib50","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cea.12369","article-title":"The presence of mast cell clonality in patients with unexplained anaphylaxis","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A\u00a0distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaci.2012.12.1578","article-title":"Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis","volume":"132","author":"van Anrooij","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.iac.2021.09.007","article-title":"Anaphylaxis and Mast Cell Disorders","volume":"42","author":"G\u00fclen","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"10.1016\/j.iac.2023.04.010_bib55","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/cea.12914","article-title":"Assessment of in\u00a0vivo mast cell reactivity in patients with systemic mastocytosis","volume":"47","author":"G\u00fclen","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib56","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/all.15277","article-title":"Mast cells derived from systemic mastocytosis exhibit an increased responsiveness to hyperosmolarity","volume":"77","author":"Lyberg","year":"2022","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2023.04.010_bib57","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2023.04.010_bib58","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.iac.2023.04.010_bib59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/ACI.0000000000000678","article-title":"Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia","volume":"20","author":"O\u2019Connell","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased a-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.iac.2023.04.010_bib62","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.jaip.2020.05.057","article-title":"Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression","volume":"8","author":"Robey","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib63","first-page":"889","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"148","author":"Chollet","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib64","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2023.04.010_bib66","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review","volume":"9","author":"G\u00fclen","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%\u00a0+2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"10.1016\/j.iac.2023.04.010_bib69","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jaip.2022.03.008","article-title":"Nontryptase urinary and hematologic biomarkers of mast cell expansion and mast cell activation: status 2022","volume":"10","author":"Butterfield","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11882-021-00988-y","article-title":"Idiopathic Anaphylaxis: a Perplexing Diagnostic Challenge for Allergists","volume":"21","author":"Gulen","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.iac.2023.04.010_bib71","first-page":"145","article-title":"Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks","volume":"8","author":"Roberts","year":"1982","journal-title":"Adv Shock Res"},{"issue":"1 Suppl","key":"10.1016\/j.iac.2023.04.010_bib72","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjmed.2013.09.008","article-title":"Recognition and first-line treatment of anaphylaxis","volume":"127","author":"Lieberman","year":"2014","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/ACI.0000000000000377","article-title":"Pharmacotherapy of mast cell disorders","volume":"17","author":"Gulen","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2023.04.010_bib74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/all.13980","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection","volume":"75","author":"Jarkvist","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2023.04.010_bib75","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000249832","article-title":"A\u00a0double-blind cross-over study of the effect of ketotifen in urticaria pigmentosa","volume":"166","author":"Czarnetzki","year":"1983","journal-title":"Dermatol"},{"key":"10.1016\/j.iac.2023.04.010_bib77","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0091-6749(90)90205-I","article-title":"Ketotifen and systemic mastocytosis","volume":"85","author":"Ting","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","article-title":"Denosumab for the treatment of osteoporosis","volume":"11","author":"Zaheer","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.iac.2014.02.001","article-title":"Neuropsychological features of adult mastocytosis","volume":"34","author":"Moura","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib80","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2023.04.010_bib81","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","article-title":"Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis","volume":"64","author":"Kontou-Fili","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2023.04.010_bib82","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.010_bib83","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2023.04.010_bib84","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2023.04.010_bib85","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2023.04.010_bib86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000329218","article-title":"Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience","volume":"157","author":"Wimazal","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib87","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"26","key":"10.1016\/j.iac.2023.04.010_bib88","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2023.04.010_bib90","first-page":"77","article-title":"Novel approaches to treating advanced systemic mastocytosis","volume":"11","author":"Gilreath","year":"2019","journal-title":"Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.010_bib91","doi-asserted-by":"crossref","first-page":"AB336","DOI":"10.1016\/j.jaci.2019.12.062","article-title":"PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent or smoldering systemic mastocytosis (SM) with symptoms inadequately controlled by standard therapy","volume":"145","author":"Akin","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2023.04.010_bib92","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.jaip.2021.02.040","article-title":"Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: prompt resolution of anaphylaxis with the addition of avapritinib","volume":"9","author":"Kudlaty","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2023.04.010_bib93","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaci.2021.02.023","article-title":"Distinct plasma biomarkers confirm the diagnosis of mastocytosis and identify increased risk of anaphylaxis","volume":"148","author":"Gulen","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:52:56Z","timestamp":1760179976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856123000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0889856123000449"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2023.04.010","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2023.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}